N/A N=499 ClotTriever Outcomes (CLOUT) Registry
Deep Vein Thrombosis Leg · DVT · Chronic DVT of Lower Extremity
Primary: Primary Safety Endpoint: Proportion Participants With Major Adverse Events — 15 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=400 Investigation of Clot in Ischemic Stroke and Hematoma Evacuation
Ischemic Stroke · Intracranial Hematoma
Primary: Clot Specimen Histology — 373; 12 Count of specimen
N/A N=200 Novel Biomarkers of Thrombotic Risk
Myocardial Infarction
Primary: Cardiovascular Event - Myocardial Infarction, Stroke, Death — 17; 6 Participants — p=0.007
N/A N=266,890 The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Venous Thromboses · Venous Thromboembolism · Deep Vein Thrombosis
Primary: Risk of Venous Thromboembolism (VTE) — 335; 845; 132; 3804 Participants
N/A N=50 The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma
Venous Thromboembolism
Primary: Hypercoagulability — 16; 18 participants
N/A N=45 Clotild® Smart Guidewire System (CSGS) Evaluation in EndovascUlar Thrombectomy Procedure
Stroke
Primary: The Proportion of Patients Having Intracranial Vessel Perforation and / or Dissection Due to Clotild® Usage at the Site of Usage in Intracranial Vessels — 0 Participants
Phase 2 N=30 Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins
Acute Deep Venous Thrombosis of the Lower Extremity
Primary: Number of Participants With Restored Venous Function — 28 participants
Phase 4 N=390 Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
COVID-19 · Venous Thromboembolism · Arterial Thrombosis
Primary: Venous or Arterial Thrombotic Events: Full-dose Anticoagulation Versus Standard-dose Prophylactic Anticoagulation — 4,486; 2,351 Number of wins — p=0.028
N/A N=25 Tranexamic Acid and Blood Clots in Knee Surgery
Venous Thrombosis
Primary: Deep Vein Thrombosis — 2 Participants
N/A N=723 Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis (PREDICTORS)
Thromboembolic Disease Recurrent · Deep Vein Thrombosis · Pulmonary Embolism
Primary: Validation of the Wells DVT Clinical Decision Rule — 67; 186; 148; 4 Participants
Early Phase 1 N=20 Sildenafil To Prevent Clot
Thrombosis · Hemolysis
Primary: Area Under the Curve for Adenosine Diphosphate (ADP) — 50; 20; 50; 6 omhs x seconds (AUC)
Phase 2 N=38 CLOTBUST Hands-Free: A Phase I/II Pilot Safety Trial
Stroke
Primary: Number of Participants in Phase I Group With Blood-brain-barrier Disruption (BBB) as Measured by MRI of the Brain — 0 participants
Phase 2 N=896 A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
Thrombosis · Hip Replacement
Primary: Adjudicated Incidence of VTE — 29.0; 20.3; 15.7; 11.5 percentage of participants with VTE — p=0.003
Phase 2 N=606 Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
Arthroplasty, Replacement, Hip · Thrombosis
Primary: Prevention of Venous Thromboembolism (VTE) — 13; 13; 10; 13 percentage of patients with event — p=0.238
Phase 4 N=20 Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
Phase 3 N=465 Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
COVID-19
Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants
Phase 3 N=120 Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery
Deep Venous Thrombosis
Primary: The Primary Outcome Measure Was the Number of Participants With New Heparin Platelet Factor 4 (HIT Positive) Antibodies in Each Group Within 30 Days Following Surgery…
N/A N=70 Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
N/A N=355 Hemostasis With QuikClot® Radial® Pad Versus TR Band® After Transradial Artery Access
Coronary Artery Disease
Primary: Initial Successful Hemostasis — 85; 88; 51; 74 Participants — p=0.906
N/A N=102 Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome
Acute Deep Vein Thrombosis
Primary: 2-year Change in Villalta Score — -1.5; -0.5 units on a scale — p=0.34
Phase 3 N=500 Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III
Intraventricular Hemorrhage
Primary: Participants With Modified Rankin Scale (mRS) <=3 - Dichotomized Analysis — 47.6; 44.9 percentage of participants — p=0.554
Phase 2 N=20 Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer
Breast Cancer
Primary: Mean Change of Tissue Factor Bearing Microparticles — 102; -618 microparticles per microliter
N/A N=324 Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System
Blood Loss, Surgical
Primary: Number of Participants With Achievement of Hemostasis at 7 Minutes — 145; 149 Participants — p=0.005
Phase 2 N=1,808 Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
Acute Non-cardioembolic Ischemic Stroke
Primary: Efficacy-Number of Participants With Composite of Symptomatic Ischemic Stroke or Covert Brain Infarcts Detected by Magnetic Resonance Imaging (MRI) — 24; 25; 17; 23…
Phase 4 N=17 Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
Arteriovenous Fistula
Primary: Clotting TIme — 6; 8 minutes
Phase 4 N=42 Clopidogrel Versus Ticagrelor in Type-2 Diabetes
Coronary Artery Disease · Diabetes Mellitus
Primary: Flow-mediated Dilation of the Brachial Artery — 16.6; 11.6 FMD (%)
Phase 2 N=207 Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
Venous Thromboembolism
Primary: Percentage of Participants With Total Venous Thromboembolism — 19; 29; 17 Participants
Phase 3 N=8,101 Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
Venous Thromboembolism
Primary: Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related…
Phase 3 N=300 Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Cerebral Vein Thrombosis · Deep Vein Thrombosis · Gonadal Thrombosis
Primary: 6 Month Bleeding Rate — 0; 2.1 percentage of patients
Phase 3 N=52 Use of a Novel Fibrin Sealant in Total Knee Arthroplasty
Osteoarthritis · Intraoperative Bleeding
Primary: Primary--Percent Change of Pre- to Post-Operative Hemoglobin — 20.1; 22.5 Percent Change — p=0.2